About biomarin pharmaceutical inc. - BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
BMRN At a Glance
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, California 94901
| Phone | 1-415-506-6700 | Revenue | 3.24B | |
| Industry | Biotechnology | Net Income | 348.90M | |
| Sector | Health Technology | 2025 Sales Growth | 14.182% | |
| Fiscal Year-end | 12 / 2026 | Employees | 3,221 | |
| View SEC Filings |
BMRN Valuation
| P/E Current | 30.803 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 32.931 |
| Price to Sales Ratio | 3.619 |
| Price to Book Ratio | 1.878 |
| Price to Cash Flow Ratio | 14.17 |
| Enterprise Value to EBITDA | 11.126 |
| Enterprise Value to Sales | 3.336 |
| Total Debt to Enterprise Value | 0.059 |
BMRN Efficiency
| Revenue/Employee | 1,006,477.491 |
| Income Per Employee | 108,320.708 |
| Receivables Turnover | 3.569 |
| Total Asset Turnover | 0.445 |
BMRN Liquidity
| Current Ratio | 5.179 |
| Quick Ratio | 3.467 |
| Cash Ratio | 2.056 |
BMRN Profitability
| Gross Margin | 77.271 |
| Operating Margin | 27.524 |
| Pretax Margin | 14.883 |
| Net Margin | 10.762 |
| Return on Assets | 4.785 |
| Return on Equity | 5.941 |
| Return on Total Capital | 5.184 |
| Return on Invested Capital | 5.365 |
BMRN Capital Structure
| Total Debt to Total Equity | 10.561 |
| Total Debt to Total Capital | 9.553 |
| Total Debt to Total Assets | 8.466 |
| Long-Term Debt to Equity | 10.419 |
| Long-Term Debt to Total Capital | 9.423 |